Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Cellular Adaptation IV: Dysplasia and Metaplasia

Cellular Adaptation IV: Dysplasia and Metaplasia

DysplasiaDysplasia refers to abnormal changes in the size, shape, and organization of mature cells, characterized by pleomorphism, nuclear abnormalities, and increased mitotic activity. It commonly affects epithelial tissues, including the cervix, gastrointestinal tract, respiratory mucosa, and endometrium. Although it may occur alongside hyperplasia, dysplasia is not a true adaptive response but a preneoplastic change with potential to progress to cancer.When confined above the basement...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability.

Cancer medicine·2026

Same author

Integrative Epigenomic and Transcriptomic Profiling Define Malignancy- and Cluster-Specific Signatures in Pheochromocytomas and Paragangliomas.

Cells·2026

Same author

Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer.

Therapeutic advances in medical oncology·2026

Same author

A patient with an adrenal metastasis and periadrenal lymph node metastases of a laryngeal squamous cell carcinoma: a case report.

Journal of medical case reports·2025

Same author

Drug repurposing in gynaecological cancers: Proven drugs for new challenges.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025

Same author

Role of GDH and PARP inhibitors as novel treatments for SDHB-deficient PPGLs.

Endocrine-related cancer·2025

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Multiple endocrine neoplasia: types 1 and 2.

Deborah J Marsh, Oliver Gimm

Advances in Oto-Rhino-Laryngology

|March 2, 2011

Summary

Multiple endocrine neoplasia (MEN) types 1 and 2 are inherited conditions causing hormone-secreting cell tumors. MEN 2 management benefits from genetic testing and prophylactic surgery, unlike MEN 1.

Area of Science:

Endocrinology
Genetics
Oncology

Background:

Multiple endocrine neoplasia types 1 (MEN 1) and 2 (MEN 2) are autosomal dominant inherited syndromes.
Germline mutations in MEN1 (loss-of-function) or RET proto-oncogene (gain-of-function) predispose to tumors in hormone-secreting cells.
MEN 1 is associated with pituitary, parathyroid, pancreatic tumors, and thymic carcinoids. MEN 2 is linked to medullary thyroid carcinoma, pheochromocytoma, and parathyroid tumors.

Purpose of the Study:

To review current knowledge of MEN 1 and MEN 2.
To emphasize aspects relevant to otorhinolaryngologists.
To compare genetic testing and management strategies for MEN 1 and MEN 2.

Main Methods:

Literature review of MEN 1 and MEN 2.

Related Experiment Videos

Last Updated: Jun 4, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Analysis of genetic mutations and associated clinical manifestations.

Comparison of diagnostic and therapeutic approaches.

Main Results:

MEN 2 management is guided by RET testing and allows for prophylactic thyroidectomy, preventing malignancy.
Genetic testing for MEN 1 is complex due to a lack of hotspots and less straightforward patient benefit.
Genotype-phenotype correlations are established for MEN 2 but absent for MEN 1.

Conclusions:

MEN 2 serves as a model for integrating molecular medicine into patient care.
Prophylactic interventions are possible for MEN 2 but not for MEN 1.
Understanding these genetic syndromes is crucial for targeted clinical management and research.